ABSTRACr The value of determining the slope of the histamine dose-response curve, in addition to the histamine provocation concentration producing a 20% reduction in FEV, (PC20OFEV), was assessed by analysis of histamine dose-response curves in 40 patients selected as having a wide range of increased non-specific bronchial responsiveness to inhaled histamine. The histamine dose-response curves were found to fit the linear curve (dose v response, mean r2 = 0-97) better than the logarithmic curve (log dose v response, mean r2 = 0-93), the difference being significant (p < 0.001). There was a strong negative correlation between the PC20-FEV, and the slope (r = -0-98, p < 0.001) and a weak negative correlation between the PC20-FEV and the log-doseresponse slope (r = -0*38, p < 0.05). Sixteen normal subjects and 16 asthmatic patients were compared on the basis of histamine dose-response curves measuring fall in sGaw. In this study there was no difference between r2 for the linear determination and for the logarithmic determination (0-91 v 0-90, p > 0-05). The PC35-,Gaw showed a strong negative correlation with the dose-response slope (r = -0-95, p < 0.01) and no correlation with the log-dose-response slope (r = 0-09, p > 0.05). In the two studies there appeared to be little information gained from the determination of either the dose-response slope or the log-dose-response slope. The slope and the PC2O-FEV, were equally reproducible, duplicate determinations showing less than a two-fold difference in 14 of 15 paired PQ0 measurements and in 13 of 15 paired slope measurements. In summary, the slope of the histamine dose-response curve appears to fit the linear model better than the logarithmic model. It is feasible to calculate it from the results of a standardised histamine inhalation test; determination of either the slope or the log-dose-response slope, however, appears to add little useful information. It is recommended that bronchial provocation test results should be expressed in terms of a threshold concentration such as the PC20-FEV, or the
summary, the slope of the histamine dose-response curve appears to fit the linear model better than the logarithmic model. It is feasible to calculate it from the results of a standardised histamine inhalation test; determination of either the slope or the log-dose-response slope, however, appears to add little useful information. It is recommended that bronchial provocation test results should be expressed in terms of a threshold concentration such as the PC20-FEV, or the PC35-sGawMeasurements of non-specific bronchial responsiveness to inhaled histamine or inhaled cholinergic agonists such as methacholine has become an important diagnostic and research aid.' 2 Inhalation tests are performed with increasing doses of the provoking agents, and the results are generally expressed either as the first dose or concentration which produces more than a predetermined response or as the interpolated dose producing a given response. For example, the histamine provocation concentration producing a 20% decline in the one-second forced expired volume (FEV,) is referred to as the histamine PC20-FEV,3 and that producing a 35% decrease in specific airway conductance (sGaw) as Address for reprint requests: Dr DW Cockcroft, University Hospital, Saskatoon, Saskatchewan, Canada, S7N OXO. the histamine PC35,Ga,W.4 Recently, however, Orehek et al suggested that a more detailed examination of bronchial provocation dose-response curves was valuable.5 These authors made a distinction between the slope of the inhaled carbachol dose-response curve, referred to-as "reactivity," and the dose causing a 25% reduction in sGaw (PC25-sGaw) referred to as "sensitivity." It was suggested that different mechanisms may determine "reactivity" -and "sensitivity," that "hyperreactivity" was more important to the asthmatic state than was "hypersensitivity," and that both should be determined when bronchial provocation tests are being interpreted.
We have developed a standardised, reproducible histamine inhalation test which has proved useful in extensive clinical research.3 6-9 Test results have 55 been expressed as the histamine PC2.FEv or the histamine PC35-SG8W. In the current study we have used this histamine inhalation test and determined the slope of the histamine dose-response curves. We have evaluated both the feasibility and the usefulness of measuring "reactivity" by this method. We have also assessed whether the histamine doseresponse slope fits the linear or the logarithmic curve better.
Methods

Subjects
Normal subjects with no history of asthma, rhinitis, or other respiratory disorder; subjects with asthma'0; and subjects with rhinitis were selected from the respiratory diseases clinic at the University Hospital in Saskatoon and from volunteers within the laboratory. Those who were taking medications were asked to refrain from using antihistamines for 48 hours and bronchodilators for eight hours; corticosteroids were continued in the same dose. The subjects were non-smokers. This investigation was approved by the ethics committee of the University of Saskatchewan and signed informed consent was obtained.
Histamine inhalation test
The standardised histamine inhalation test was performed as previously outlined.37 After a control inhalation of normal saline, doubling concentrations of histamine acid phosphate from 0*03 to 8*0 mg/ml were inhaled for two minutes at five-minute intervals. Inhalations were made via a face mask from a Wright nebuliser operated with an airflow rate of 7 I/min and with 5 ml of solution in the vial. The output of the nebuliser was 0-130 ml/min and the particle size mass median diameter 1 ,um. Forty subjects were selected to participate in the study. All were known to have increased bronchial responsiveness to inhaled histamine with a histamine PC20FEV, of less than 8-0 mg/ml. They included 30 with bronchial asthma, six with rhinitis, and four normal individuals with mildly increased responses to histamine. The subjects were selected to represent a wide range of bronchial responsiveness; their PC20s ranged from 006 to 8*0 mg/ml.
The histamine PC20-FEV and both the dose-response slope and the log dose-response slope were calculated from each of the 40 curves. Determination of the slopes of the dose-response curves was based on two points in nine subjects, three points in 26 subjects and four points in five subjects.
Logarithmic transformation of PC20 and of slope of the dose-response curve, but not the slope of the log dose-response curve, was required for the analysis. Firstly, the coefficients of determination (r2) of the slope of the linear dose-response curve and of the slopes of the log dose-response curve (from the 31 curves with more than two points) were compared by means of the paired t test.'2 Secondly, correlation between the PC20-FEV, and the slopes of both the linear and the log dose-response curves was sought by the method of least-squares linear regression. " Finally, the 20 subjects with the highest and the 20 with the lowest log-dose-response slopes were compared with a view to finding differences in clinical features; Student's t test13 and the x2 test"' were used.
STUDY NO 2: PC35-soaw
The second study was carried out to compare asthmatic with normal subjects. Sixteen patients with well-documented asthma'0 and 16 normal subjects participated. All had a 30% or greater reduction in sGaw after inhalation of the top concentration (8 mg/ml) of histamine-that is, the PC35s-Gaw was less than 10 mg/ml. We had to test 36 normal subjects to find 16 with a 30% reduction in sGaw after 8 mg/ml of histamine. Histamine dose-response curves were obtained and the PC35-SGaw was determined as well as the slopes of the dose-response curve and the log-dose-response curve. Determination of the slopes was based on two points in two subjects, three points in 19 subjects, four points in 10 subjects, and five points in one subject.
The analysis was performed in the same way as in the first study. The figure 1 . There was a more than 100-fold range in PC20 values, from 0*06 to 8-0 mg/ml; and there was a similar range in slopes, values ranging from 3 to 460 (% fall/mg/ml). There was a strong negative correlation between the PC20 and the slope (r = -0-98, p < 0-001), the slope of the curve being larger in subjects with a low PC20. Only one subject fell outside the 95% confidence of limits of this regression (fig 1) . The histamine PC20 was then compared with the slope of the log-doseresponse curve (fig 2) . The range of the values for this slope was smaller, from 12 to 90 (% fall/log mg/ml). There was a weak negative correlation between the PC20 and the log-dose-response slope (r = -0-38, p < 0-05). In an effort to determine whether there was any significance in the differences better than a logarithmic model. '6 We found that the slope of the histamine doseresponse curve showed a strong negative correlation both with the PC2Ev, and with the PC35-.5aw (r = -0-98 and -0*95 respectively). This shows that both increasing dose-response slopes and decreasing PC20 or PC35 reflect increasing bronchial responsiveness to inhaled histamine. The very close correlation, especially with PC20, suggests that the measurements may be used interchangeably, and that with knowledge of the PC20 one could accurately predict the slope of the curve. Thus the slope appears to provide little added information. These results are at variance with those of Orehek et al, who showed no correlation between the slope of the carbachol dose-response curve and the PC25-sGSw5
That study used a cumulative carbachol dose response curve,s whereas ours used a dose-response curve based on histamine, which has been previously shown to have no cumulative effect.7 There are other differences in the design of the studies which might be relevant in explaining the difference. Orehek et al studied a smaller number of subjects with a narrower range of bronchial responses, the range for PC25.8Gaw being only 20-fold.5 A second difference is that they produced a greater fall in sGaw in all subjects, attempting to achieve a 75% reduction in all and reaching at least a 50% reduction in all. Whether the differences between our results and those of Orehek et al are due to inherent differences between histamine and cholinergic agonists, to differences between cumulative and non-cumulative dose-response curves, or to other technical factors is not clear.
Although the log-dose-response slope was not as accurate a description of the curve as the linear, it did provide a reasonable fit (r2 = 0-93 and 0.90). The log-dose-response slope showed only a weak negative correlation with PC2o.EZv and no correlation with PC35SGaw. The relatively narrow range for the values of this log-dose-response slope, in conjunction with the small or absent trend in the regressions when they were plotted against PC20 and PC35, shows that the log-dose-response slopes are nearly parallel throughout the entire range of bronchial responsiveness, being only slightly steeper at the more responsive end in the PC20-FEv, regression (fig 2) . This is consistent with the observation of Hargreave et al, who showed parallel log-doseresponse curves for inhaled histamine.'7 There was no difference in the log-dose-response slope between 16 normal and 16 asthmatic subjects and there was little difference in the clinical features of the Cockcroft, Berscheid subjects with the high slopes and those with the low slopes in the FEV, study. The PC20, as expected from the regression, was slightly lower and there was an unexpected and unexplained higher proportion of atopic subjects in those with the high slopes. Thus the log-dose-response slope also fails to add any obvious useful information when it is determined from the results of histamine inhalation tests by this technique.
Using a different approach, Beaupre and Malo have also examined the clinical usefulness of determining the slope of the histamine dose-response curve."8 They found that changes in the histamine PC20-FEv, for individual asthmatic patients correlated with changes in clinical state and that similar information was not available from the slope of the curve.
From this investigation we can draw the following conclusions. Firstly, even though the method fails to fulfil all the theoretical criteria for accurate assessment of the slope of a dose-response curve, it is feasible to obtain a reasonable measurement of the slope of the histamine dose-response curve with our standardised inhalation technique. Secondly, the slope of the dose-response curve, within the range of responses that we measured, appears to fit a linear curve better than a logarithmic curve. Thirdly, the high correlation between the slope and PC20 (or PC3, ) indicates that little information is gained by determining both from the bronchial provocation dose-response curve. Finally, the less significant log-dose-response slope correlated poorly with PC20 and PC35 and also appeared to add little information that was not available from the determination of the PC20 (or PC35) alone. We suggest that the easiest and most useful measurement of non-specific bronchial responsiveness to inhaled histamine or a cholinergic agonist is a measurement of so-called sensitivity such as the PC20-FEV., or the PC35-sGW.
